RT @BrainTumorInst: A two-arm study evaluating palbociclib in patients with recurrent #glioblastoma. From C. David James, PhD, and @Neurosu…
RT @BrainTumorInst: A two-arm study evaluating palbociclib in patients with recurrent #glioblastoma. From C. David James, PhD, and @Neurosu…
RT @BrainTumorInst: A two-arm study evaluating palbociclib in patients with recurrent #glioblastoma. From C. David James, PhD, and @Neurosu…
A two-arm study evaluating palbociclib in patients with recurrent #glioblastoma. From C. David James, PhD, and @NeurosurgUCSF colleagues in @JNeurooncol: https://t.co/9pndx6h0W3 https://t.co/neizNRiF4V
#elderly #gliomas Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. https://t.co/ih1hrJP9dT
RT @BrainTumorInst: Our scientific director, David James, PhD, joins @JennieWTaylor and other @NeurosurgUCSF colleagues in evaluating the e…
Our scientific director, David James, PhD, joins @JennieWTaylor and other @NeurosurgUCSF colleagues in evaluating the efficacy and tissue pharmacokinetics/pharmacodynamics of palbociclib in patients with recurrent #glioblastoma. New in @JNeurooncol: http